Pfizer (NYSE:PFE) Shares Down 1.4% – What’s Next?

Pfizer Inc. (NYSE:PFE) shares traded down 1.4% during mid-day trading on Friday . The company traded as low as $28.38 and last traded at $28.42. Approximately 23,419,310 shares changed hands during mid-day trading, a decline of 44% from the average daily volume of 41,591,715 shares. The stock had previously closed at $28.81.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched the Phase 3 VESPER-JM study of obesity candidate berobenatide in Japan. The trial strengthens Pfizer’s effort to compete in the rapidly expanding obesity-drug market and supports management’s expectation that the product could contribute to growth from 2028 onward. Pfizer Steps Up in Obesity Race With New Phase 3 Berobenatide Trial in Japan
• Positive Sentiment: Pfizer’s Phase 3 tilrekimig eczema program provides another late-stage pipeline catalyst, while the completed Phase 1 migraine-tablet study demonstrates continued efforts to diversify beyond COVID-19 products. Pfizer’s Tilrekimig Eczema Trial
• Positive Sentiment: The FDA approved Pfizer’s 2026–2027 COMIRNATY XFG COVID-19 vaccine formula for high-risk age groups, supporting near-term vaccine sales and adding to the recent run of favorable company news. Pfizer After FDA Vaccine Approval Faces A Fair Value Reality Check
• Positive Sentiment: Pfizer licensed its early-stage CD228V antibody-drug conjugate to Medicus Pharma in a deal potentially worth more than $1 billion plus royalties. The agreement provides external validation and possible future economic upside, although the asset remains clinically unproven. Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
• Neutral Sentiment: Pfizer recently reported earnings above expectations, and shares are up substantially over the past year. Analysts now question how much of the pipeline and vaccine optimism is already reflected in the stock, limiting the impact of additional positive headlines. Pfizer Stock Looks Fully Valued As Earnings Run Ahead Of Value
• Negative Sentiment: Investor concerns remain focused on declining post-pandemic revenue, upcoming patent expirations and Pfizer’s ability to maintain its roughly 6% dividend while funding new growth initiatives. Some commentary characterizes the stock as a potential value trap despite its low valuation and high yield. Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Bank of America reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research report on Tuesday, June 9th. UBS Group reaffirmed a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. Guggenheim reduced their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Finally, Wolfe Research restated an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $28.28.

Pfizer Stock Performance

The stock’s 50 day moving average is $25.90 and its two-hundred day moving average is $26.33. The firm has a market capitalization of $161.98 billion, a P/E ratio of 37.40, a P/E/G ratio of 1.95 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. The ex-dividend date was Friday, July 24th. Pfizer’s dividend payout ratio is 226.32%.

Hedge Funds Weigh In On Pfizer

A number of large investors have recently bought and sold shares of the company. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Keb Asset Management LLC bought a new stake in Pfizer during the second quarter worth $26,000. Field & Main Bank acquired a new stake in Pfizer in the second quarter valued at $27,000. HFM Investment Advisors LLC grew its position in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Finally, Evolution Wealth Management Inc. increased its stake in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.